Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | CASP2 | P42575 | 1/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.54 |
| ▸ | ICMT | O60725 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9285558 | 1.00 | NAAA (0.55) | NAAACASP2DNM1ICMTALB | |
| SCHEMBL9290501 | 0.99 | CASP2 (0.56) | NAAACASP2DNM1ICMTALB | |
| SCHEMBL25607772 | 0.99 | NAAA (0.57) | NAAACASP2DNM1ICMTALB | |
| SCHEMBL9290503 | 0.99 | NAAA (0.57) | NAAACASP2DNM1ICMTALB | |
| SCHEMBL9290528 | 0.99 | CASP2 (0.56) | NAAACASP2DNM1ICMTALB | |
| SCHEMBL9288264 | 0.97 | CASP2 (0.54) | NAAACASP2DNM1ICMTALB | |
| SCHEMBL25607883 | 0.97 | CASP2 (0.54) | NAAACASP2DNM1ICMTALB | |
| SCHEMBL652484 | 0.97 | NAAA (0.58) | NAAACASP2DNM1ICMTALB | |
| SCHEMBL12792093 | 0.97 | NAAA (0.58) | NAAACASP2DNM1ICMTALB | |
| SCHEMBL12792190 | 0.97 | NAAA (0.58) | NAAACASP2DNM1ICMTALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181742-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2023-06-15 | — | — | US | disclosed |
| US-20230181742-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181742-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | SNRPA, NUDT21, SOAT2 | NAAA 99/4885CASP2 1820/4885DNM1 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.